AR048587A1 - Composiciones quimicamente estables de 4-hidroxitamoxifeno - Google Patents

Composiciones quimicamente estables de 4-hidroxitamoxifeno

Info

Publication number
AR048587A1
AR048587A1 ARP050101125A ARP050101125A AR048587A1 AR 048587 A1 AR048587 A1 AR 048587A1 AR P050101125 A ARP050101125 A AR P050101125A AR P050101125 A ARP050101125 A AR P050101125A AR 048587 A1 AR048587 A1 AR 048587A1
Authority
AR
Argentina
Prior art keywords
approximately
hydroxy tamoxifen
chemically stable
compositions
hydroxithamoxifen
Prior art date
Application number
ARP050101125A
Other languages
English (en)
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of AR048587A1 publication Critical patent/AR048587A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere a composiciones químicamente estables de 4-hidroxitamoxifeno. La potencia de las composiciones no es afectada adversamente por la isomerizacion que se produce entre estas dos formas. Las composiciones son utiles para la prevencion o para el tratamiento de afecciones médicas, entre otras, cáncer de mama. Reivindicacion 1: Una composicion farmacéutica en el estado de equilibrio que comprende 4-hidroxitamoxifeno, en donde existe aproximadamente 45%-55%, aproximadamente 46%-54%, aproximadamente 47%-53%, aproximadamente 48%-52%, aproximadamente 49%-51% o aproximadamente 50% de dicho 4-hidroxitamoxifeno en una forma isomérica Z y el remanente de dicho 4-hidroxitamoxifeno existe en una forma isomérica E.
ARP050101125A 2004-03-22 2005-03-22 Composiciones quimicamente estables de 4-hidroxitamoxifeno AR048587A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/805,530 US20050208139A1 (en) 2004-03-22 2004-03-22 Chemically stable compositions of 4-hydroxy tamoxifen
EP04290762A EP1579857A1 (en) 2004-03-22 2004-03-22 Chemically stable compositions of 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
AR048587A1 true AR048587A1 (es) 2006-05-10

Family

ID=34854723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101125A AR048587A1 (es) 2004-03-22 2005-03-22 Composiciones quimicamente estables de 4-hidroxitamoxifeno

Country Status (22)

Country Link
US (1) US20050208139A1 (es)
EP (4) EP1579857A1 (es)
JP (1) JP5489407B2 (es)
CN (1) CN101080222B (es)
AR (1) AR048587A1 (es)
AT (1) ATE453387T1 (es)
AU (1) AU2005227073B2 (es)
CA (1) CA2557806C (es)
DE (1) DE602005018613D1 (es)
DK (1) DK1727532T3 (es)
ES (3) ES2402921T3 (es)
HK (2) HK1098674A1 (es)
IL (2) IL177778A (es)
MX (1) MXPA06010928A (es)
NO (1) NO337298B1 (es)
NZ (1) NZ549664A (es)
PL (1) PL1727532T3 (es)
PT (1) PT1727532E (es)
RU (1) RU2389483C2 (es)
TW (1) TWI401078B (es)
WO (1) WO2005092310A2 (es)
ZA (1) ZA200607291B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296757A1 (en) * 2002-12-18 2004-07-09 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
MXPA05006526A (es) 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
EP1952810B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
PT1631275E (pt) 2003-06-09 2008-08-04 Ascend Therapeutics Inc Tratamento e prevenção da cicatrização excessiva com 4-hidroxi-tamoxifeno
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
KR101294947B1 (ko) * 2004-10-14 2013-08-09 라보라뚜아르 베쟁 인터네셔널 4-히드록시 타목시펜 겔 제제
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
CA2775266C (en) * 2009-10-13 2013-12-31 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
CN103945832B (zh) * 2011-07-14 2017-03-29 能脑有限责任公司 用于脑能量分子延迟释放和持续释放的组合物，装置及方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US5475851A (en) * 1986-04-14 1995-12-12 National Instruments Corporation Method and apparatus for improved local and global variable capabilities in a graphical data flow program
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6160549A (en) * 1994-07-29 2000-12-12 Oracle Corporation Method and apparatus for generating reports using declarative tools
DE4435784C2 (de) * 1994-10-06 1998-10-29 Heraeus Electro Nite Int Elektrisch beheizbarer Starterkat
US5777621A (en) * 1994-12-22 1998-07-07 Apple Computer, Inc. Quality control mechanism for three-dimensional graphics rendering
EP0883587A1 (en) * 1996-01-20 1998-12-16 Bradford University Tamoxifen and analogues thereof
DE59703511D1 (de) * 1996-03-29 2001-06-13 S W Patentverwaltungs Ges M B Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
JP2001527037A (ja) * 1997-12-23 2001-12-25 ヘキサル アーゲー Ｚ−４−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成
JP2000038335A (ja) * 1998-07-22 2000-02-08 Kanebo Ltd 皮膚化粧料
AU6890800A (en) 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
US6695171B2 (en) * 2002-02-12 2004-02-24 Seaquistperfect Dispensing Foreign, Inc. Pump dispenser
AU2003296757A1 (en) * 2002-12-18 2004-07-09 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
EP1952810B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
PT1631275E (pt) * 2003-06-09 2008-08-04 Ascend Therapeutics Inc Tratamento e prevenção da cicatrização excessiva com 4-hidroxi-tamoxifeno
EP1694319B1 (en) * 2003-12-15 2008-07-16 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
CN101080222B (zh) 2013-08-07
TWI401078B (zh) 2013-07-11
AU2005227073A1 (en) 2005-10-06
IL177778A0 (en) 2006-12-31
EP2269599B1 (en) 2013-02-20
WO2005092310A2 (en) 2005-10-06
ZA200607291B (en) 2008-04-30
EP2147670A1 (en) 2010-01-27
RU2006137282A (ru) 2008-04-27
ES2517894T3 (es) 2014-11-04
MXPA06010928A (es) 2006-12-15
EP1579857A1 (en) 2005-09-28
CN101080222A (zh) 2007-11-28
WO2005092310A3 (en) 2005-12-01
DK1727532T3 (da) 2010-05-03
NO337298B1 (no) 2016-03-07
EP2147670B1 (en) 2014-10-01
HK1098674A1 (en) 2007-07-27
PT1727532E (pt) 2010-03-30
TW200533334A (en) 2005-10-16
ES2402921T3 (es) 2013-05-10
IL177778A (en) 2011-12-29
CA2557806C (en) 2011-08-30
US20050208139A1 (en) 2005-09-22
DE602005018613D1 (de) 2010-02-11
PL1727532T3 (pl) 2010-06-30
IL215897A0 (en) 2011-12-29
EP2269599A1 (en) 2011-01-05
JP5489407B2 (ja) 2014-05-14
RU2389483C2 (ru) 2010-05-20
ATE453387T1 (de) 2010-01-15
EP1727532B1 (en) 2009-12-30
EP1727532A2 (en) 2006-12-06
NZ549664A (en) 2011-01-28
AU2005227073B2 (en) 2011-06-23
HK1139332A1 (en) 2010-09-17
IL215897A (en) 2014-09-30
CA2557806A1 (en) 2005-10-06
JP2007530498A (ja) 2007-11-01
ES2337069T3 (es) 2010-04-20
NO20064765L (no) 2006-10-20

Similar Documents

Publication Publication Date Title
AR048587A1 (es) Composiciones quimicamente estables de 4-hidroxitamoxifeno
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
DOP2020000023A (es) Nuevos derivados de quinolina
CR9987A (es) Compuestos de lactama y métodos de uso de los mismos
CL2023003021A1 (es) Moduladores de la proteólisis bcl6 y métodos de uso asociados,
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
AR109263A2 (es) Composición que comprende moxidectina
CO2021015624A2 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
UY35293A (es) Isotiazoles sustituidos con amino
UY37832A (es) Dihidrooxadiazinonas
BR112019000849A2 (pt) composições líquidas de limpeza com sistema antibacteriano e método de fabricação das mesmas
SV2007002235A (es) Nuevos derivados de pirimidina y su uso ref. bhc041311-sv
CO2020013876A2 (es) Nuevos derivados de quinolina
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
UY29627A1 (es) Derivados de prostaglandina
CL2008003027A1 (es) Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY29417A1 (es) Agentes endoparasiticidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure